We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NAII:NASDAQNatural Alternatives International, Inc. Analysis

Data as of 2026-07-10 - not real-time

$2.24

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at roughly $2.24, which sits below its 20‑day SMA of about $2.42 and the 50‑day SMA of $2.54, signaling a bearish price trend. Momentum indicators are mixed: the RSI is deep in oversold territory at 27, while the MACD line remains below its signal, producing a negative histogram, and volume has been trending lower, suggesting weakening buyer interest. Price is hovering just above the identified support level near $2.21, with resistance around $2.71, and the 30‑day volatility is high at roughly 36%, reflecting a choppy market environment.
Fundamentally, the company shows revenue growth of 23% to $142 M, yet profitability is severely compromised with negative gross, operating, and net margins, and cash flow is negative. The balance sheet is strained, featuring debt of $65 M versus cash of $9 M and a debt‑to‑equity ratio exceeding 100%. Valuation multiples are extremely low (price‑to‑book ~0.22, price‑to‑sales ~0.10) and there is no dividend, while the market’s fear‑greed index is in the “Extreme Greed” zone, indicating heightened speculative sentiment.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages
  • RSI indicating oversold conditions but MACD bearish
  • Decreasing volume and proximity to support

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained negative earnings and cash flow
  • High debt‑to‑equity ratio and limited liquidity
  • Low valuation multiples offset by financial distress

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside from low price‑to‑book and price‑to‑sales
  • Exposure to growing supplement contract manufacturing market
  • Structural balance‑sheet weaknesses requiring turnaround

Key Metrics & Analysis

Financial Health

Revenue Growth23.30%
Profit Margin-10.13%
ROE-20.57%
ROA-2.47%
Debt/Equity103.26
P/B Ratio0.2
Op. Cash Flow$-4505000
Free Cash Flow$-2995125

Technical Analysis

TrendBearish
RSI27.1
Support$2.21
Resistance$2.71
MA 20$2.42
MA 50$2.54
MA 200$2.98
MACDBearish
VolumeDecreasing
Fear & Greed Index92.95

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.74
Volatility35.95%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.